Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 10/2011

01-10-2011 | Letter

Thoracolaparoscopic esophagectomy: further improvement in the multimodal treatment of esophageal cancer

Author: Theodore Liakakos

Published in: Surgical Endoscopy | Issue 10/2011

Login to get access

Excerpt

Standardization of multimodal treatment can improve the oncological outcome of patients with a new diagnosis of potentially completely resectable esophageal cancer. Preoperative (neoadjuvant) chemoradiotherapy can improve survival of not only these patients but also those with initially advanced, nonmetastatic, nonresectable with curative intent carcinoma of thoracic esophagus or gastroesophageal junction cancer. A recent study reports that if a complete response (CR) is achieved when assessed with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET), then prognosis is excellent [1]. However, this three-mode treatment is associated with a substantial rate of surgical complications and adverse effects of adjuvant treatment. Postoperative complications after an open thoracoabdominal, transhiatal, or transthoracic approach represent even today a serious problem with fatal outcome. With standardization of surgery, particularly in high-volume centers, the rates of surgical morbidity and mortality have dropped. How could this morbidity and short-term postoperative quality of life be improved? …
Literature
1.
Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW (2010) Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28(31):4714–4721PubMedCrossRef
2.
Puntambekar SP, Agarwal GA, Joshi SN, Rayate NV, Sathe RM, Patil AM (2010) Thoracolaparoscopy in the lateral position for esophageal cancer: the experience of a single institution with 112 consecutive patients. Surg Endosc 24(10):2407–2414PubMedCrossRef
3.
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555PubMedCrossRef
4.
Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476PubMedCrossRef
5.
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350PubMedCrossRef
6.
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651PubMedCrossRef
7.
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406PubMedCrossRef
8.
Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef
9.
Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef
10.
Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRef
11.
Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRef
12.
Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef
13.
Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48PubMedCrossRef
14.
Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782PubMedCrossRef
15.
Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126PubMedCrossRef
16.
Roukos DH (2011) “Big” science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123–126PubMedCrossRef
17.
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250.PubMedCrossRef
18.
Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRef
19.
Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRef
20.
Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996PubMedCrossRef
21.
Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef
22.
Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92PubMedCrossRef
23.
Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef
24.
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRef
Metadata
Title
Thoracolaparoscopic esophagectomy: further improvement in the multimodal treatment of esophageal cancer
Author
Theodore Liakakos
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 10/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-011-1691-4

Other articles of this Issue 10/2011

Surgical Endoscopy 10/2011 Go to the issue

OriginalPaper

Mesh fixation compared to nonfixation in total extraperitoneal inguinal hernia repair: a randomized controlled trial in a rural center in India

Letter--Reply

Reply to doi: 10.1007/s00464-011-1692-3: Totally laparoscopic total gastrectomy and the challenge of esophagojejunostomy

OriginalPaper

Novel handheld PET probes provide intraoperative localization of PET-avid lymph nodes

OriginalPaper

Laparoscopic fixation of biologic mesh at the hiatus with fibrin or polyethylene glycol sealant in a porcine model

Video

Laparoscopic right hepatectomy and partial resection of the diaphragm for liver metastases

Dynamic Manuscript

Laparoscopic resection of the uncinate process of the pancreas: the inframesocolic approach and hanging maneuver of the mesenteric root